On May 22, 2025 OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, reported it has entered into a collaboration agreement with Mayo Clinic (Press release, Mayo Clinic, MAY 22, 2025, View Source [SID1234653340]). The agreement provides OncoSwab with access to clinical research expertise and know-how to support the development of its nasal swab-based diagnostic platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration centers on enabling clinical validation of OncoSwab’s lead diagnostic test, which utilizes genomic biomarkers from nasal fluid to detect lung cancer and expanding the technology into additional indications.

"Our goal is to deliver accurate, accessible diagnostics that empower clinicians to detect cancer earlier and with greater ease" said Andrea Stephany Díaz, co-founder and CEO of OncoSwab.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.